Cardiac Amyloidosis Market Analysis, Size, Share & Growth Forecast 2026–2034

Tafamidis ATTR-ACT 30 Percent All-Cause Mortality Reduction Over 30 Months in ATTR-CM Has Established TTR Tetramer Stabilisation as the Validated Disease-Modifying Mechanism for the Restrictive Cardiomyopathy That Previously Had No Approved Disease-Specific Treatment.Pfizer's Vyndaqel and Vyndamax 61 mg and 80 mg generated over USD 3.5 billion in 2024 revenue after ATTR-ACT demonstrated 29.5% relative mortality reduction and 32% hospitalisation reduction versus placebo, establishing TTR stabilisation as the first pharmacologic treatment for a cardiac disease previously managed only supportively. The growing commercial success of tafamidis reflects both genuine need in an undertreated population and improved ATTR-CM diagnosis through increased ECG awareness, bone scintigraphy diagnosis, and cardiac biopsy, which has identified a prevalent condition previously undiagnosed in patients presenting with heart failure and preserved ejection fraction. BridgeBio Pharma's acoramidis in ATTRIBUTE-CM demonstrated non-inferior TTR stabilisation with superior cardiac biomarker improvement versus placebo at 30 months, creating direct competition to tafamidis and providing an alternative stabiliser with a differentiated clinical profile.

NTLA-2001 CRISPR-Cas9 LNP In Vivo Liver Gene Editing 87 Percent TTR Reduction From Single IV Infusion Has Demonstrated the One-Time Gene Editing Approach That Permanently Silences the Amyloidogenic TTR Gene Without Repeated Dosing.Alnylam Pharmaceuticals's patisiran and vutrisiran demonstrated TTR reduction of 80-88% through RNAi-mediated hepatic TTR mRNA silencing, and HELIOS-B Phase 3 data for vutrisiran in ATTR-CM demonstrated significant cardiovascular mortality and morbidity reduction that positioned vutrisiran for ATTR-CM approval alongside its existing polyneuropathy label. The TTR silencing approach eliminates hepatic TTR production rather than stabilising already-formed TTR tetramers, potentially preventing the accumulation of misfolded TTR that continues despite stabiliser therapy in established cardiac amyloidosis. Ionis Pharmaceuticals and AstraZeneca's eplontersen antisense oligonucleotide and Novo Nordisk's investigational TTR siRNA provide additional silencing modalities that are advancing in clinical development for both cardiac and neurological manifestations of hereditary ATTR amyloidosis.

Acoramidis ATTRibute-CM Phase III All-Cause Mortality Improvement From Near-Complete TTR Stabilisation Is Positioning the Next-Generation Stabiliser as the Potentially Superior Treatment to the Partial Tafamidis Stabilisation for ATTR Cardiac Amyloidosis.Technetium pyrophosphate bone scintigraphy has become the primary non-biopsy diagnostic for wild-type ATTR-CM, achieving Grade 2-3 cardiac uptake that provides 99% positive predictive value for ATTR-CM in the absence of light-chain amyloidosis, and institutional diagnostic programmes at major heart failure centres have increased ATTR-CM diagnosis rates ten-fold over pre-awareness baseline. AI-enhanced ECG algorithms from AliveCor and Tempus trained to identify the low-voltage and pseudo-infarct pattern of ATTR-CM are being deployed in primary care and emergency department ECG review to flag undiagnosed patients for confirmatory scintigraphy referral. The expanding diagnosis creates a growing treated population that translates directly to tafamidis, acoramidis, and emerging TTR silencer prescriptions, as essentially all patients diagnosed with ATTR-CM without contraindication to TTR-targeted therapy are candidates for commercially available treatment.

For related market intelligence, see the Cardiomyopathy Market.